Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Latest News

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

View Press Release View All

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

Recent Event

Second Quarter 2022 Financial Results

View Event View All

Latest Financial Results

Q2 2022

Quarter Ended Jun 30, 2022
Earnings Release
PDF HTML
Audio
Earnings Webcast
Earnings Presentation
PDF
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Report Links

mail icon

Sign Up For Email Alerts

Receive updates straight into your inbox

Sign up today

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080

Investor Relations

Rigel Pharmaceuticals, Inc.
ir@rigel.com

Transfer Agent

EQ Shareowner Services
T: 800-401-1957